Healthcare | The Pharma Letter | 17 May 2017

Partnering to address the rising cost of clinical trials

The cost of the clinical trial process today is upwards of $100mn. So how can drug developers with robust R&D pipelines but a limited operating budget make the most of their portfolios and get as many promising new therapies to market in the narrow window before patents expire? In a word, partnerships. In this article, Ben van der Schaaf at Arthur D. Little discusses why by working with CROs, universities, and patient advocacy organizations, innovative drug makers can find investors who see their intellectual property as a valuable starting point for the drug development process.

Healthcare | Pharmaphorum | 15 May 2017

New funding models to progress low-priority clinical trials

The cost of funding a clinical trial today can run biopharma companies upwards of $100mn, and that does not even begin to consider the costs of marketing and distribution necessary for a new life enhancing therapy to reach patients' hands. Global pharma businesses that spent the last decade building a robust pipeline of early stage compounds and indications are now faced with a wide portfolio of potential assets without the resources to fund their development. The result? Drug makers who've made the investments necessary to ensure a strong R&D pipelines are now losing billions each year in potential revenue as promising new therapies are sitting dormant, waiting for their patent to expire. In this article, Ben van der Schaaf at Arthur D. Little discusses new funding models to progress low-priority clinical trials.

Healthcare | Infrastructure Intelligence | 15 November 2016

Is the car industry about to change for good?

In its "Global Automotive Mobility Study", experts from Arthur D. Little shed light on the three megatrends of autonomous driving: electric mobility and car sharing.

Healthcare | International Journal of Healthcare Management | 13 November 2016

Embracing digital health in the Pharmaceutical Industry

Disruptive innovations challenge pharma companies to change up business models and value chains to stay ahead. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how as the industry becomes more digitalized, pharma companies will need to implement changes that will ultimately lead to new business models and value chains.

Healthcare | European Biopharmaceutical Review | 15 July 2016

From the Outside

Innovation from sources outside of the traditional healthcare system is changing the pharma industry. A digital revolution in many business models means a positive overall change for patient care - but introducing new services too quickly could see development in other areas suffering. In this article Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz from Arthur D. little discuss the impact of digital health on the pharmaceutical industry.

Healthcare | International Pharmaceutical Industry | 01 June 2016

Digital health: increasing the quality and efficiency of care

It is becoming clear that in order to stay relevant in the future healthcare ecosystem, pharma companies must look to business models that foster much more direct patient engagement than previously. New methods offer significant potential in increasing the quality and efficiency of care. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz from Arthur D. Little explain how digital health solutions can solve the major long-term issues of pharma’s most important client groups – patients, providers and payers – all at the same time.

Healthcare | Drug Discovery World | 01 May 2016

Digital pharma – responding to challenges and opportunities from outside

Innovation has always been one of the foundations for success in the pharmaceutical industry. While the sector has been very good at developing innovation from scratch or incremental innovation of existing products, it now faces an ultimately differently challenge - dealing with disruptive innovation that is driven by inventions outside the healthcare sector. New players from the digital arena are currently redefining the way the industry works. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how digital is reshaping the pharma arena.

Healthcare | Healthcare Market News | 01 May 2016

Transforming the value chain with digital health

The business model of the pharmaceutical industry is being transformed by digital health. It will significantly extend current business models, or even create completely new ones for the industry. In order to implement innovative solutions ahead of new entrants, pharma companies will need to undergo major transformation programs and convert three completely different value chains: pharma, medical devices for measuring health parameters, and IT solutions to process and connect data. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how pharma companies can get ahead of disruptive innovations and thrive in the digital world.

Healthcare | Scrip Intelligence | 01 April 2016

Digital Health Disruption

Investment in the digital healthcare space has never been greater than in 2015, and looks set to continue its upward trajectory in 2016. Healthcare delivery models are changing, placing empowered patients at the center of the traditional pharma ecosystem. Now pharma must fully embrace digital opportunities or risk losing a huge piece of its own future. In this article, a report from Arthur D. Little is quoted as saying that by 2020, the traditional pharma business model will be turned on its head.

Healthcare | Pharmaphorum | 22 March 2016

Applying outside innovation to healthcare

Companies with new technologies and approaches are entering healthcare, and challenging pharma's traditional dominance in the sector. Today we are already seeing pharma companies such as Merck (through its patient engagement platform, Merckengage) and AbbVie (with a video solution for the management of Parkinson's Disease with Karolinska University Hospital) making initial steps towards offering a range of basic services that support important areas such as patient compliance, adherence or interdisciplinary collaboration. In this article, the authors explain why the world can expect many more innovations to be applied to healthcare by pharma companies.

| |Bookmark Arthur D. Little